antiparasitic/inflammation

BACKGROUND OF THE INVENTION Most nucleated eukaryotic cells, whether unicellular organisms or constituents of multicellular organism including humans, contain acidified vacuoles that are critical for cellular maintenance and function. In mammalian cells, these vacuoles comprise lysosomes and other

The present invention relates to novel cyclosporins, their use as pharmaceuticals and pharmaceutical compositions comprising them, as well as to processes for the production of said novel cyclosporins and novel intermediates. The cyclosporins comprise a class of structurally distinctive, cyclic,

The present invention relates to novel cyclosporins, their use as pharmaceuticals and pharmaceutical compositions comprising them, as well as to processes for the production of said novel cyclosporins and novel intermediates. The cyclosporins comprise a class of structurally distinctive, cyclic,

BACKGROUND OF THE INVENTION (a) Field of the Invention This invention relates to 4,5-dihydro-5-oxopyrazolo[1,5-a]quinazoline-3-carboxylic acids and esters and alkali metal salts thereof useful as anti-inflammatory, anti-allergic and anti-parasitic agents. (B) Description of the Prior Art Wright, J.

FIELD OF THE INVENTION The present invention relates generally to the field of anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents, and more particularly, the invention relates to a family of bifunctional heterocyclic compounds useful as such an agent. BACKGROUND The

CROSS-REFERENCE TO RELATED APPLICATIONS Not applicable. BACKGROUND 1. Field of Invention This is a new use utility patent for a multi-purpose skin balm series produced by compounding already FDA approved drugs generally regarded as safe. Skin Balm For Psoriasis is the flagship product of this

The present invention relates to novel cyclosporins, processes for their production, their use as pharmaceuticals and pharmaceutical compositions comprising them. The cyclosporins comprise a class of structurally distinctive, cyclic, poly-N-methylated undecapeptides commonly possessing

The present invention relates to novel cyclosporins, processes for their production, their use as pharmaceuticals and pharmaceutical compositions comprising them. The cyclosporins comprise a class of structurally distinctive, cyclic, poly-N-methylated undecapeptides commonly possessing

CROSS-REFERENCE TO RELATED APPLICATIONS This application is a National Stage filing under 35 U.S.C. .sctn. 371 of International Patent Application No. PCT/CN2013/077796, filed on Jun. 24, 2013, entitled "Use of Ivermectin and Derivatives Thereof", which claims the benefit of and priority to Chinese

BACKGROUND OF THE INVENTION Field of the Invention This invention is generally in the field of therapeutic delivery systems, including genetically engineered probiotic and attenuated bacteria compositions and methods for providing co-expression of protease inhibitors with plasmids, phage, phagmids

CROSS REFERENCE TO RELATED APPLICATION The present application is a non-provisional of U.S. Provisional Application No. 61/764,577, filed Feb. 14, 2013, the entirety of which is expressly incorporated herein by reference. 1. BACKGROUND OF THE INVENTION 1.1. Field of the Invention This invention is

BACKGROUND OF THE INVENTION Platinum complexes, the prototype of cisplatin, have been widely used as active anticancer agents (Ardizzoni et al., 1999; Nitiss, 2002) in a variety of human tumors, including testicular, ovarian, bladder carcinoma, head and neck, and non-small cell lung cancers. The

BACKGROUND OF THE INVENTION Cellular responses to growth factors and cytokines are characterized by activation of the Signal Transducer and Activator of Transcription (STAT) family of cytoplasmic transcription factors (Darnell, 1997; Darnell et al., 1994; Schindler et al., 1995; Stark et al., 1998;

BACKGROUND OF THE INVENTION Platinum complexes, the prototype of cisplatin, have been widely used as active anticancer agents (Ardizzoni et al., 1999; Nitiss, 2002) in a variety of human tumors, including testicular, ovarian, bladder carcinoma, head and neck, and non-small cell lung cancers. The

BACKGROUND OF THE INVENTION Cellular responses to growth factors and cytokines are characterized by activation of the Signal Transducer and Activator of Transcription (STAT) family of cytoplasmic transcription factors (Darnell, 1997; Darnell et al., 1994; Schindler et al., 1995; Stark et al., 1998;